17 completed, 8 terminated, 6 withdrawn, 4 recruiting. 19 Phase 2, 8 Phase 3, 3 Phase 4, 2 Early Phase 1, 2 Not applicable.
Follow this condition Literature Review of Pyoderma trials Research Report on Pyoderma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum Bimekizumab - Pyoderma Gangrenosum | Phase 2 | Not yet recruiting | Oregon Health and Science University | 15 | 2026-09-01 | 2026-08-17 |
| Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum topical ruxolitinib 1.5% cream - Pyoderma Gangrenosum | Phase 2 | Recruiting | Oregon Health and Science University | 12 | 2026-09-01 | 2026-10-09 |
| A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum SHR-1139 Injection - Pyoderma Gangrenosum | Phase 2 | Not yet recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 20 | 2026-03-05 | 2026-03-03 |
| A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum SHR-1139 Injection - Pyoderma Gangrenosum | Phase 2 | Recruiting | Shandong First Medical University | 10 | 2026-01-29 | 2026-09-09 |
| A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum Spesolimab, Placebo matching to spesolimab, Prednisone - Pyoderma Gangrenosum | Phase 3 | Recruiting | LEO Pharma | 90 | 2025-02-05 | 2026-09-02 |
| Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) Guselkumab - Pyoderma Gangrenosum, Skin Diseases | Phase 2 | Active not recruiting | Oregon Health and Science University | 17 | 2025-02-01 | 2026-09-28 |
| Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum Platelet rich plasma therapy - Pyoderma Gangrenosum | Not applicable | Withdrawn | Ohio State University | 2024-05-28 | 2025-08-11 | |
| Deucravacitinib in PG Deucravacitinib - Pyoderma Gangrenosum | Early Phase 1 | Withdrawn | Dartmouth-Hitchcock Medical Center | 2024-04-29 | 2025-06-27 | |
| Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum vilobelimab, Placebo - Pyoderma Gangrenosum | Phase 3 | Terminated | InflaRx GmbH | 54 | 2023-11-01 | 2025-11-04 |
| Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Baricitinib - Pyoderma Gangrenosum, Skin Diseases | Phase 2 | Completed | Oregon Health and Science University | 5 | 2023-10-03 | 2025-05-13 |
| Spesolimab in Pyoderma Gangrenosum Spesolimab - Pyoderma Gangrenosum | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 5 | 2023-09-23 | 2026-03-31 |
| Painless Sharp Wound Debridement With Lidocaine-23%-Tetra-caine-7% Gel Versus EMLA 5% Cream IMP2 (lidocaine-23%-tetracaine-7% gel), IMP1 (EMLA 5% cream) - Ulcus Cruris, Ecthyma | Phase 2 | Unknown | Juerg Hafner | 40 | 2023-06-01 | 2023-06-06 |
| Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma Hydroxymethylquinoxalindioxyde, Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium - Pyoderma | Phase 3 | Completed | Valenta Pharm JSC | 240 | 2022-07-19 | 2023-10-10 |
| Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum Hyperbaric oxygen, Control group - Pyoderma Gangrenosum | Phase 3 | Terminated | Erasmus Medical Center | 3 | 2022-06-01 | 2024-09-19 |
| JAK-STAT Signaling Pathway in Pyoderma Gangrenosum immunohistochemical methods - Pyoderma Gangrenosum, Hidradenitis Suppurativa | Unknown | Dokuz Eylul University | 120 | 2022-05-01 | 2022-03-23 | |
| A Novel Therapeutic Treatment of Pyoderma Gangrenosum Dehydrated human amnion/chorion membrane - Pyoderma Gangrenosum | Phase 4 | Terminated | Louisiana State University Health Sciences Center in New Orleans | 5 | 2021-06-02 | 2025-10-15 |
| Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma Monoclonal antibody (Mab) sB24M - Pyoderma, Pyoderma Gangrenosum | Early Phase 1 | Completed | SWISS BIOPHARMA MED GmbH | 10 | 2021-05-24 | 2023-03-20 |
| Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum secukinumab 150 mg (2 injections per dose - Pyoderma Gangrenosum | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-05-28 | |
| A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG) Pyoderma Gangrenosum | Completed | AbbVie | 60 | 2021-02-12 | 2025-07-17 |
Showing 20 of 43. Sign in to see all of them.
Pyoderma Gangrenosum (36) · Scabies (4) · Crohn Disease (3) · Skin Ulcer (3) · Calciphylaxis (2) · Colitis, Ulcerative (2) · Leg Ulcer (2) · Pressure Ulcer (2) · Skin Diseases (2) · Varicose Ulcer (2) · Wounds and Injuries (2) · Acute Generalized Exanthematous Pustulosis (1) · Arthritis, Juvenile (1) · Behcet Syndrome (1)
Skin and Connective Tissue Diseases (43) · Skin Diseases (41) · Skin Diseases, Vascular (36) · Skin Ulcer (34) · Infections (7) · Skin Diseases, Infectious (6) · Bacterial Infections (4) · Bacterial Infections and Mycoses (4) · Cardiovascular Diseases (4) · Ectoparasitic Infestations (4) · Mite Infestations (4) · Parasitic Diseases (4) · Skin Diseases, Parasitic (4) · Vascular Diseases (4)
gevokizumab (4) · Adalimumab (3) · secukinumab (2) · spesolimab (2) · vilobelimab (2) · Antibodies, Monoclonal (1) · Control Groups (1) · Hyperbaric Oxygenation (1) · IGF2BP2 protein, human (1) · Infliximab (1) · Lidocaine, Prilocaine Drug Combination (1) · Oxygen (1) · Prednisolone (1) · Prednisone (1) · Respiration (1)
Oregon Health and Science University (4) · XOMA (US) LLC (4) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · AbbVie (2) · InflaRx GmbH (2) · Ohio State University (2) · University of Zurich (2) · Wake Forest University Health Sciences (2) · Arena Pharmaceuticals (1) · Assistance Publique Hopitaux De Marseille (1) · Dartmouth-Hitchcock Medical Center (1) · Dokuz Eylul University (1) · Erasmus Medical Center (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Icahn School of Medicine at Mount Sinai (1)
United States (21) · Australia (6) · Switzerland (5) · Canada (4) · China (3) · Fiji (3) · France (3) · Germany (3) · Japan (3) · Poland (3) · Belgium (2) · Italy (2) · Spain (2) · Argentina (1) · Austria (1)
Alex G Ortega-Loayza, MD, MCR (2) · Alex GO Loayza, Prof, MD (1) · Alexander Navarini, MD (1) · Alison Smith, MD, PhD (1) · Anthony D Ormerod, MBChB (1) · Arena CT.gov Administrator (1) · Bart Currie, MBBS, DTM&H (1) · Benjamin H. Kaffenberger, MD (1) · Benjamin Kaffenberger, MD (1) · Brian J. Simmons, MD (1) · Caroline E Fife, MD (1) · Christine Connors, MBBS (1) · Colin J Parker, MBBS (1)